HUP0200049A2 - Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses - Google Patents

Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Info

Publication number
HUP0200049A2
HUP0200049A2 HU0200049A HUP0200049A HUP0200049A2 HU P0200049 A2 HUP0200049 A2 HU P0200049A2 HU 0200049 A HU0200049 A HU 0200049A HU P0200049 A HUP0200049 A HU P0200049A HU P0200049 A2 HUP0200049 A2 HU P0200049A2
Authority
HU
Hungary
Prior art keywords
ige
domain
epitopes
subject
epsilon
Prior art date
Application number
HU0200049A
Other languages
Hungarian (hu)
Inventor
Michael Dyson
Martin Friede
Judith Greenwood
Ellen Hewitt
Alan Lamont
Sean Mason
Mechelen Marcelle Paulette Van
Roger Randall
William Gordon Turnell
Y De Bassols Carlota Vinals
Original Assignee
Peptide Therapeutics Ltd
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904405.9A external-priority patent/GB9904405D0/en
Priority claimed from GBGB9907151.6A external-priority patent/GB9907151D0/en
Priority claimed from GBGB9910538.9A external-priority patent/GB9910538D0/en
Priority claimed from GBGB9910537.1A external-priority patent/GB9910537D0/en
Priority claimed from GBGB9918603.3A external-priority patent/GB9918603D0/en
Priority claimed from GBGB9918594.4A external-priority patent/GB9918594D0/en
Priority claimed from GBGB9921047.8A external-priority patent/GB9921047D0/en
Priority claimed from GBGB9921046.0A external-priority patent/GB9921046D0/en
Priority claimed from GBGB9925619.0A external-priority patent/GB9925619D0/en
Priority claimed from GBGB9927698.2A external-priority patent/GB9927698D0/en
Application filed by Peptide Therapeutics Ltd, Smithkline Beecham Biolog filed Critical Peptide Therapeutics Ltd
Publication of HUP0200049A2 publication Critical patent/HUP0200049A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány tárgya allergiás betegség kezelésére, megelőzésére, vagyjavítására szolgáló gyógyszerek biztosítása. A gyógyszerek előnyösenizolált peptidek, amelyek IgE Ce2 doménjének felszíni részeinekepitópjait vagy mimotópjait tartalmazzák. Így találtuk, hogy ezenrégiók mind aktív, mind passzív immunprofilaxis vagy immunterápiacélpontja lehetnek. A találmány tárgyát képezik továbbá eljárások agyógyszerek előállítására, azokat tartalmazó készítmények, és azokalkalmazása gyógyhatású anyagban. A találmány tárgyát képezikligandumok, előnyösen monoklonális ellenanyagok is, amelyek képesek azIgE találmány szerinti felszíni kitettségű régióihoz kötődni, és azokalkalmazása gyógyhatású anyagban passzív immunterápiaként vagyimmunprofilaxisban. ÓThe subject of the invention is the provision of medicines for the treatment, prevention or improvement of allergic diseases. The drugs are preferably isolated peptides containing epitopes or mimotopes of the surface parts of the Ce2 domain of IgE. Thus, we found that these regions can be targets for both active and passive immunoprophylaxis or immunotherapy. The subject of the invention are also methods for the production of medicines, preparations containing them, and their use in medicinal substances. The subject of the invention is also ligands, preferably monoclonal antibodies, which are capable of binding to the surface-exposed regions of IgE according to the invention, and their use in a medicinal substance as passive immunotherapy or in immunoprophylaxis. HE

HU0200049A 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses HUP0200049A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GBGB9904405.9A GB9904405D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9907151.6A GB9907151D0 (en) 1999-03-29 1999-03-29 Therapeutic antibody composition and use
GBGB9910538.9A GB9910538D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions ansd uses
GBGB9910537.1A GB9910537D0 (en) 1999-05-07 1999-05-07 Therapeutic antibody, Immunogenic compositions and uses
GBGB9918603.3A GB9918603D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918594.4A GB9918594D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9921047.8A GB9921047D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody, immunogenic compositions & uses
GBGB9921046.0A GB9921046D0 (en) 1999-09-07 1999-09-07 Therapeutic antibody composition & use
GBGB9925619.0A GB9925619D0 (en) 1999-10-29 1999-10-29 Vaccine
GBGB9927698.2A GB9927698D0 (en) 1999-11-23 1999-11-23 Therapeutic antibody

Publications (1)

Publication Number Publication Date
HUP0200049A2 true HUP0200049A2 (en) 2002-05-29

Family

ID=27579426

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200049A HUP0200049A2 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses

Country Status (19)

Country Link
EP (1) EP1155037A1 (en)
JP (1) JP2004538238A (en)
KR (1) KR20020007313A (en)
CN (1) CN1348466A (en)
AR (1) AR029336A1 (en)
AU (1) AU2672700A (en)
BR (1) BR0008963A (en)
CA (1) CA2363637A1 (en)
CO (1) CO5210906A1 (en)
CZ (1) CZ20013082A3 (en)
HK (1) HK1044004A1 (en)
HU (1) HUP0200049A2 (en)
IL (1) IL145024A0 (en)
MX (1) MXPA01008613A (en)
NO (1) NO20014130L (en)
NZ (1) NZ513679A (en)
PL (1) PL350993A1 (en)
TR (1) TR200102506T2 (en)
WO (1) WO2000050460A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913327D0 (en) * 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
EP1497318A4 (en) * 2001-04-18 2006-03-01 Dyax Corp Binding molecules for fc-region polypeptides
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
WO2008099188A1 (en) * 2007-02-15 2008-08-21 Astrazeneca Ab Binding members for ige molecules
AR065368A1 (en) * 2007-02-15 2009-06-03 Astrazeneca Ab ANTIBODIES FOR IGE MOLECULES
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
EP3882274A4 (en) * 2018-09-21 2022-06-29 Riken Anti-ige antibody specifically binding to membrane-bound ige antibody of ige antibody-producing b cells and method for diagnosing and treating allergic symptoms using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
WO1998024808A2 (en) * 1996-12-06 1998-06-11 THE UNITED STATES OF AMERICA represented by THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES, THE NATIONAL INSTITUTES OF HEALTH INHIBITION OF IgE-MEDIATED ALLERGIES BY A HUMAN IgE-DERIVED OLIGOPEPTIDE
JP2001516009A (en) * 1997-07-17 2001-09-25 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Cancer-related nucleic acids and polypeptides

Also Published As

Publication number Publication date
CN1348466A (en) 2002-05-08
KR20020007313A (en) 2002-01-26
PL350993A1 (en) 2003-02-24
TR200102506T2 (en) 2002-06-21
NO20014130D0 (en) 2001-08-24
NO20014130L (en) 2001-09-13
NZ513679A (en) 2001-09-28
AU2672700A (en) 2000-09-14
MXPA01008613A (en) 2003-06-24
IL145024A0 (en) 2002-06-30
CO5210906A1 (en) 2002-10-30
JP2004538238A (en) 2004-12-24
BR0008963A (en) 2001-11-27
CA2363637A1 (en) 2000-08-31
EP1155037A1 (en) 2001-11-21
HK1044004A1 (en) 2002-10-04
AR029336A1 (en) 2003-06-25
CZ20013082A3 (en) 2002-02-13
WO2000050460A1 (en) 2000-08-31

Similar Documents

Publication Publication Date Title
MXPA01008612A (en) Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses.
HUP0301789A2 (en) Recombinant anti-cd40 antibody and uses thereof
DE60229979D1 (en)
UY28170A1 (en) PREPARATION AND TREATMENT FOR DEMIELINIZING DISEASES AND PARALYSIS THROUGH THE APPLICATION OF REMIELINIZING AGENTS.
ATE230417T1 (en) PEPTIDE IMMUNOGENS FOR VACCINATION AGAINST AND TREATMENT OF ALLERGIES
WO2002074337A8 (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EA200601132A1 (en) PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE
WO2002072636A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2003092624A3 (en) Use of heat shock proteins to enhance efficacy of antibody therapeutics
MX364381B (en) Rapidly dispersible dosage form of oxcarbazepine.
ATE419872T1 (en) PREVENTIVE AND THERAPEUTIC MONOCLONAL ANTIBODIES AGAINST VACCINIAVIRUS ANTIGENS
IL138424A0 (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
WO2008016431A3 (en) Bi-specific monoclonal antibody (specific for both cd3 and cd11b) therapeutic drug
HUP0200049A2 (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses
WO2002102320A3 (en) Fce fusion proteins for treatment of allergy and asthma
EA200400134A1 (en) THERAPEUTIC AGENT
ATE277625T1 (en) PHARMACEUTICAL COMPOSITION OF SPIDER VENOM AND THEREOF PRODUCTION AND USE FOR THE TREATMENT OF TUMOR DISEASES
ATE247466T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING IBUPROFEN AND DOMPERIDONE FOR THE TREATMENT OF MIGRAINES
WO2002034288A8 (en) Vaccine for treating allergy
ATE338819T1 (en) ANTIGENIC PROTEIN FROM MALASSEZIA
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
WO2003092714A3 (en) Peptide variants of ige constrained by beta-lactam bond
DE50110274D1 (en) DRUGS FOR IMMUNOTHERAPY MALIGNER TUMORS
EA200401295A1 (en) STATIN THERAPY TO ENHANCE SUPPORT OF COGNITIVE FUNCTION
DE69420574T2 (en) DERIVATIVES OF THERAPEUTICALLY EFFECTIVE PEPTIDES IN THE BLOOD COLLECTING CASCADE, METHOD FOR THE PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME